Combinaison gliptine-gliflozine dans le traitement du diabete de type 2.

[en] Type 2 diabetes (T2D) is a complex disease with multiple defects, which generally require a combination of several pharmacological approaches to control hyperglycaemia. Combining a dipeptidyl peptidase-4 inhibitor (DPP-4i) and a sodium-glucose cotransporter type 2 inhibitor (SGT2i) appears to be an attractive approach because the two drugs exert different and potentially complementary glucose-lowering effects. Dual therapy (initial combination or stepwise approach) is more potent than either monotherapy in patients treated with diet and exercise or already treated with metformin. Combining the two pharmacological options is safe and does not induce hypoglycaemia. Two fixed-dose combinations (FDCs) are already available (saxagliptin-dapagliflozin and linagliptin-empagliflozin) and others are in current development.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège > Département des sciences cliniques > Département des sciences cliniques

Paquot, Nicolas ; Université de Liège > Département des sciences de la santé publique > Diabétologie, nutrition et maladies métaboliques

Language :

French

Title :

Combinaison gliptine-gliflozine dans le traitement du diabete de type 2.

Alternative titles :

[en] Gliptin-gliflozin combination for treating type 2 diabetes

Publication date :

2016

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Issue :

527

Pages :

1384-1388

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 08 September 2017

Statistics

Number of views

663 (9 by ULiège)

Number of downloads

782 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-42.
Scheen AJ, Paquot N. Actualisation 2015 du traitement de l'hyperglycémie dans le diabète de type 2. Rev Med Suisse 2015;11:1518-25.
Scheen AJ, Paquot N. Intérêt d'une combinaison agoniste des récepteurs du GLP-1 et insuline basale dans le traitement du diabète de type 2. Rev Med Suisse 2014;10:1549-54.
Barnett AH, Charbonnel B, Moses RG, et al. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus. Curr Med Res Opin 2015;31:1919-31.
Guthrie RM. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Postgrad Med 2015;127:463-79.
Scheen AJ. A review of gliptins for 2014. Exp Opin Pharmacother 2015;16:43-62.
Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf 2015;14:505-24.
Scheen AJ. Gliptines, sécurité cardiovasculaire et insuffisance cardiaque: le point après l'étude TECOS. Rev Med Suisse 2015;11:1526-33.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT 2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59.
Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509-14.
Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508.
Scheen AJ, Paquot N. Metabolic effects of SGLT 2 inhibitors beyond increased glucosuria: A review of clinical evidence. Diabetes Metab 2014;40:S4-S11.
Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium glucose cotransporter 2 (SGLT 2) inhibition. Diabetes Care 2015;38:1730-5.
Scheen AJ. SGLT 2 inhibition: Efficacy and safety in type 2 diabetes treatment. Exp Opin Drug Safety 2015;14:1879-904.
Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis. Diabetes Obes Metab 2016; epub ahead of print.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
Scheen AJ, Wallemacq C, Jandrain BJ, et al. Protection cardiovasculaire du patient diabétique de type 2: d'EMPA-REG OUTCOME à LEADER. Rev Med Suisse 2016;12:1370-5.
Scheen AJ. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Diabetes Metab 2016;42:71-6.
Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in EMPA-REG OUTCOME: Comparison with classic diuretics. Diabetes Metab 2016;42, epub ahead of print.
Scirica BM, Braunwald E, Raz I, et al. Heart failure, Saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial. Circulation 2015;132:e198.
Sharma MD. Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes. Diabetes Obes Metab 2015;17:616-21.
Abdul-Ghani M. Where does combination therapy with an SGLT 2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes Care 2015;38:373-5.
Aronson R. Single-pill combination therapy for type 2 diabetes mellitus: Linagliptin plus empagliflozin. Curr Med Res Opin 2015;31:901-11.
Woo V. Empagliflozin / linagliptin single-tablet combination: First-inclass treatment option. Int J Clin Pract 2015;69:1427-37.
Williams DM, Stephens JW. Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 2015;16:2373-9.
Vakkalagadda B, Vetter ML, Rana J, et al. Bioequivalence of saxagliptin / dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects. Pharmacol Res Perspect 2015;3:e00201.
Hansen L, Iqbal N, Ekholm E, et al. Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract 2014;20:1187-97.
Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015;38:376-83.
Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care 2015;38: 2009-17.
Matthaei S, Catrinoiu D, Celinski A, et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care 2015;38:2018-24.
Kim ES, Deeks ED. Empagliflozin / Linagliptin: A review in type 2 diabetes. Drugs 2015;75:1547-57.
Triplitt C, Solis-Herrera C, Cersosimo E, et al. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2015;16:2819-33.
Tan X, Hu J. Empagliflozin / Linagliptin: Combination therapy in patients with type 2 diabetes. Ann Endocrinol (Paris) 2016; epub ahead of print.
Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther 2013;35:A33-42.
Rauch T, Graefe-Mody U, Deacon CF, et al. Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus. Diabetes Ther 2012;3:10.
Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 2015;38:394-402.
DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38:384-93.
Plosker GL. Canagliflozin: A review of its use in patients with type 2 diabetes mellitus. Drugs 2014;74:807-24.
Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obesity Metab 2016;18:82-91.
Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebocontrolled study. Diabetes Care 2014;37:740-50.